Nevertheless, because HDAC inhibitors are being actively investigated as potential therapeutic agents for a number of diseases including diabetes (Christensen et al., 2011), it will be important to determine whether such inhibitors increase circulating free fatty acid concentrations, which would likely worsen insulin resistance and possibly have adverse effects in diabetes. This evidence concerns the gene HDAC9 and diabetes mellitus.